WO2025153898 - RETINOID COMPOSITIONS AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2025/153898
Publication Date
24.07.2025
International Application No.
PCT/IB2025/000029
International Filing Date
17.01.2025
Title **
[English]
RETINOID COMPOSITIONS AND METHODS OF USE
[French]
COMPOSITIONS RÉTINOÏDES ET PROCÉDÉS D'UTILISATION
Applicants **
GENE COMPANY PTY LTD
Inventors
WANG, Cheng, Chi
Priority Data
2024900129
19.01.2024
AU
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP Australia
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 9485 | |
| EPO | Filing, Examination, Granting | 332402 | |
| Japan | Filing, Examination, Granting | 5884 | |
| South Korea | Filing, Examination, Granting | 18873 | |
| USA | Filing, Examination, Granting | 58390 |
Total:
425,034
Contact Us
Abstract[English]
Described herein are retinoid compositions comprising (a) a retinoid preferably a C20-deuterated vitamin A that inhibits dimerisation to N-retinylidene-N-retinylethanolamine (A2E), (b) a lipid excipient preferably an omega-3 fatty acid comprising eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), and (c) a surfactant, wherein the compositions increase the bioavailability of the retinoid in a subject, and methods of using such retinoid compositions for treating eye conditions including macular degeneration.[French]
L'invention concerne des compositions de rétinoïde comprenant (a) un rétinoïde de préférence une vitamine A deutérée en C20 qui inhibe la dimérisation en N-rétinylidène-N-rétinyléthanolamine (A2E), (b) un excipient lipidique, de préférence un acide gras oméga-3 comprenant de l'acide eicosapentaénoïque (EP A) ou de l'acide docosahexaénoïque (DHA), et (c) un tensioactif, les compositions augmentant la biodisponibilité du rétinoïde chez un sujet, et des procédés d'utilisation de telles compositions de rétinoïde pour traiter des affections oculaires comprenant la dégénérescence maculaire.